

# European Patent Office grants patent for Guard Therapeutics' candidate ROSgard

**Guard Therapeutics AB (publ.) announces that the European Patent Office (EPO) today has granted a patent for the company's biological investigational drug ROSgard, both as a product and for its medical use. The patent provides protection in Europe until 2037.**

The patent has been granted as EP 3430032 B1 and follows on the previously issued Intention to Grant notice, which was communicated by the company in April 2021. The granted patent covers the company's lead investigational drug ROSgard as a product ("composition of matter") and intellectual property rights for other similar compounds, as well as their medical use. The granted patent confers protection for ROSgard in Europe until 2037.

In addition to the present Grant in Europe, Guard Therapeutics recently obtained grant of the corresponding patents in the US and Australia. The company has pending patent applications for ROSgard in several other major countries, including Japan, China, India, Canada and Brazil.

**For further information, please contact:**

---

## **Tobias Agervald, CEO**

Telephone: +46 8 670 65 51

E-mail: [info@guardtherapeutics.com](mailto:info@guardtherapeutics.com)

## **About Guard Therapeutics**

---

Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

## **Attachments**

---

[European Patent Office grants patent for Guard Therapeutics' candidate ROSgard](#)